Trial · NCT04317781
Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant
NCT04317781, Phase 2, Terminated, M.D. Anderson Cancer Center; results first posted 2024-07-16
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant. Trials, record NCT04317781. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04317781
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Tagraxofusp in Treating Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm After Stem Cell Transplant
- NCT number
- NCT04317781
- Status
- Terminated
- Phases
- Phase 2
- Enrollment
- 3 participants, actual
- Lead sponsor
- M.D. Anderson Cancer Center
- Conditions
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Interventions
- Tagraxofusp-erzs
- First posted
- 2020-03-23
- Last updated
- 2024-07-31
- Results first posted
- 2024-07-16
- Limitations and caveats
- The protocol was terminated early due to slow participant accrual and the sponsor not willing to provide the study drug.~Stemline is the funder, not the sponsor.
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Number of Participants That Received Planned Tagraxofusp Post Transplant | Up to 1 year | Participants completed at least 75% of planned tagraxofusp doses in at least 4 cycles of therapy. |
| Secondary | Progression Free Survival (PFS) | From treatment start date to date of disease progression or death, assessed up to 1 year | Participant alive and disease free one year post transplant |
| Secondary | Overall Survival (OS) | From treatment start date to death, assessed up to 1 year | Number of participants alive one year post transplant |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Number of Participants That Received Planned Tagraxofusp Post Transplant | Up to 1 year | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Progression Free Survival (PFS) | From treatment start date to date of disease progression or death, assessed up to 1 year | Participants | COUNT_OF_PARTICIPANTS | |
| SECONDARY | Overall Survival (OS) | From treatment start date to death, assessed up to 1 year | Participants | COUNT_OF_PARTICIPANTS |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Number of Participants That Received Planned Tagraxofusp Post Transplant | Treatment (Tagraxofusp-erzs) | 1 | Participants | ||
| Progression Free Survival (PFS) | Treatment (Tagraxofusp-erzs) | 2 | Participants | ||
| Overall Survival (OS) | Treatment (Tagraxofusp-erzs) | 2 | Participants |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Treatment (Tagraxofusp-erzs) | 3 | |
| Overall Study | COMPLETED | Treatment (Tagraxofusp-erzs) | 0 | |
| Overall Study | NOT COMPLETED | Treatment (Tagraxofusp-erzs) | 3 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Elevated Transaminases | Investigations | Treatment (Tagraxofusp-erzs) | 1 | 3 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Treatment (Tagraxofusp-erzs) | 1 | 3 |
| Total, other adverse events | Treatment (Tagraxofusp-erzs) | 1 | 3 |
| Total, serious adverse events | Treatment (Tagraxofusp-erzs) | 0 | 3 |
Source ClinicalTrials.gov
Papers1
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as |
|---|---|
| 33795208 | DERIVED |
Source PubMed
Grants1
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years |
|---|---|---|---|---|---|
| P30CA016672 | The University of Texas MD Anderson Cancer Center Support Grant (CCSG) | KOONG, ALBERT | UNIVERSITY OF TX MD ANDERSON CAN CTR | NATIONAL CANCER INSTITUTE | 1985 to 2026 |
Source NIH RePORTER
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT04317781
GET https://conductscience.org/api/trials/v1/NCT04317781/registered